GE HealthCare Technologies Inc. (GEHC) Form 8-K — Oct 28, 2026
$GEHCForm 8-KItems 2.02, 5.02, 9.01Filed Oct 28, 2026, 6:25 AM ET0001932393-26-000058Original filing
GE HealthCare reported strong Q3 2026 results with revenue of $5.5 billion, up 7.2%, and diluted EPS of $1.36, up 39.1% year-over-year, both ahead of company expectations. Adjusted EBIT margin expanded 180 bps to 16.6%, and free cash flow of $793 million rose 64.2%. The company raised its full-year 2026 guidance, now expecting organic revenue growth of ~4.0% and adjusted EPS of $4.95-$5.05, up from the prior $4.80-$5.00 range. Backlog stands at $23.7 billion with a 1.03x book-to-bill, and the quarterly dividend was raised 14% to $0.04 per share.
Key figures
- Eps
- 1.36
- Revenue
- 5513
- Guidance
- Raised FY2026: Organic revenue growth ~4.0%; Adjusted EBIT margin 15.5%-15.7%; Adjusted EPS $4.95-$5.05; Free cash flow $1.6B+
- Net Income
- 615
- Total Debt
- $10.0 billion
- Revenue Yoy
- 7.2%
- Total Assets
- 38371
- Cash Position
- $2.9 billion
- Backlog
- $23.7 billion
- Adjusted eps
- 1.34
- Book to bill
- 1.03x
- Adjusted ebit
- 913
- Free cash flow
- 793
- Quarterly dividend
- $0.04 per share (up 14%)
- Operating cash flow
- 907
- Adjusted ebit margin
- 16.6%
- Organic orders growth
- 4.0%
- Organic revenue growth
- 6.2%
- Sofie acquisition price
- $945 million cash
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.